Pharmacology

Chronic Obstructive Pulmonary Disease, Second Edition

Volumn , Issue , 2012, Pages 341-356

  Costello, Richard ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33745129929     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b13457-29     Document Type: Chapter

References (161)

1. Olsen C, Colebatch H, Mebel P, Nadel J, Staub N. Motor control of pulmonary airways studied by nerve stimulation. J Appl Physiol 1965;20:202-8.
2. Brody JS, Klempfner G, Staum MM, Vidyasagas D, Kuhl DE, Waldhausen JA. Mucociliary clearence after lung denervation and bronchial transection. J Appl Physiol 1972;32:160-4.
3. Gallagher JT, Kent PW, Passatore M, Phipps RJ, Richardson PS. The composition of tracheal mucus and the nervous control of its secretion in the cat. Proc R Soc Lond 1976;192:49-76.
4. McCormack DG, Mak JC, Minette P, Barnes PJ. Muscarinic receptor subtypes mediating vasodilation in the pulmonary artery. Eur J Pharmacol 1988;158:293-7.
5. Coleridge HM, Coleridge JC. Neural regulation of bronchial blood flow. Respir Physiol 1994;98:1-13.
6. Mann SP. The innervation of mammalian bronchial smooth muscle: the localization of catecholamines and cholinesterases. Histochemistry 1971;3:319-31.
7. Richardson JB. Nerve supply to the lungs. Am Rev Respir 1979;119:785-802.
8. O’Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:542-9.
9. O’Donnell DE, Lam M, Webb KA. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;158:1557-65.
10. Severinghaus JW, Stupfel M. Respiratory dead space increases following atropine in man and atropine, vagal or ganglionic blockade and hypothermia in dogs. J Appl Physiol 1955;8:81-6.
11. Douglas NJ, Sudlow MF, Flenley DC. Effect of an inhaled atropinelike agent on normal airway function. J Appl Physiol 1979;46:256-62.
12. Gross NJ, Co E, Skorodin MS. Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects. Chest 1989;96:984-7.
13. Hulme EC, Kurtenbach E, Curtis CA. Muscarinic acetylcholine receptors: structure and function. Biochem Soc Trans 1991; 19:133-8.
14. Lechleiter J, Peralta E, Clapham D. Diverse functions of muscarinic acetylcholine receptor subtypes. Trends Pharmacol Sci 1989;(suppl):34-8.
15. Ramachandran J, Peralta EG, Ashkenazi A, Winslow JW, Capon DJ. The structural and functional interrelationships of muscarinic acetylcholine receptor subtypes. Bioessays 1989; 10:54-7.
16. Mak JC, Barnes PJ. Muscarinic receptor subtypes in human and guinea pig lung. Eur J Pharmacol 1989;164:223-30.
17. Mak JC, Barnes PJ. Autoradiographic visualization of muscarinic receptor subtypes in human and guinea pig lung. Am Rev Respir Dis 1990;141:1559-68.
18. Mak JC, Baraniuk JN, Barnes PJ. Localization of muscarinic receptor subtype mRNAs in human lung. Am J Respir Cell Mol Biol 1992;7:344-8.
19. Haddad EB, Mak JC, Hislop A, Haworth SG, Barnes PJ. Characterization of muscarinic receptor subtypes in pig airways: radioligand binding and northern blotting studies. Am J Physiol 1994;266:L642-8.
20. Haddad EB, Mak JC, Belvisi MG, Nishikawa M, Rousell J, Barnes PJ. Muscarinic and beta-adrenergic receptor expression in peripheral lung from normal and asthmatic patients. Am J Physiol 1996;270:L947-53.
21. Buckley NJ, Bonner TI, Buckley CM, Brann MR. Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. Mol Pharmacol 1989;35:469-76.
22. Wess J, Blin N, Mutschler E, Bluml K. Muscarinic acetylcholine receptors: structural basis of ligand binding and G protein coupling. Life Sci 1995;56:915-22.
23. Wess J. Molecular basis of receptor/G-protein-coupling selectivity. Pharmacol Ther 1998;80:231-64.
24. Wess J, Liu J, Blin N, Yun J, Lerche C, Kostenis E. Structural basis of receptor/G protein coupling selectivity studied with muscarinic receptors as model systems. Life Sci 1997;60: 1007-14.
25. Casale TB, Ecklund P. Characterization of muscarinic receptor subtypes on human peripheral lung. J Appl Physiol 1988; 65:594-600.
26. Myers AC, Undem BJ, Weinreich D. Electrophysiological properties of neurons in guinea pig bronchial parasympathetic ganglia. Am J Physiol 1990;259:L403-9.
27. Koyama S, Rennard SI, Robbins RA. Acetylcholine stimulates bronchial epithelial cells to release neutrophil and monocyte chemotactic activity. Am J Physiol 1992;262:L466-71.
28. Ueda F, Ban K, Ishima T. Irsogladine activates gapjunctional intercellular communication through M1 muscarinic acetylcholine receptor. J Pharmacol Exp Ther 1995;274:815-19.
29. Yang B, McCaffrey TV. The roles of muscarinic receptor subtypes in modulation of nasal ciliary action. Rhinology 1996;34:136-9.
30. Yang B, Schlosser RJ, McCaffrey TV. Signal transduction pathways in modulation of ciliary beat frequency by methacholine. Ann Otol Rhinol Laryngol 1997;106:230-6.
31. Fryer AD, Maclagan J. Muscarinic inhibitory receptors in pulmonary parasympathetic nerves in the guinea-pig. Br J Pharmacol 1984;83:973-8.
32. Blaber LC, Fryer AD, Maclagan J. Neuronal muscarinic receptors attenuate vagally-induced contraction of feline bronchial smooth muscle. Br J Pharmacol 1985;86:723-8.
33. Patel HJ, Barnes PJ, Takahashi T, Tadjkarimi S, Yacoub MH, Belvisi MG. Evidence for prejunctional muscarinic autoreceptors in human and guinea pig trachea. Am J Respir Crit Care Med 1995;152:872-8.
34. Ramnarine SI, Haddad EB, Khawaja AM, Mak JC, Rogers DF. On muscarinic control of neurogenic mucus secretion in ferret trachea. J Physiol 1996;494:577-86.
35. Sankary RM, Jones CA, Madison JM, Brown JK. Muscarinic cholinergic inhibition of cyclic AMP accumulation in airway smooth muscle. Role of a pertussis toxin-sensitive protein. Am Rev Respir Dis 1988;138:145-50.
36. Fernandes LB, Fryer AD, Hirshman CA. M2 muscarinic receptors inhibit isoproterenol-induced relaxation of canine airway smooth muscle. J Pharmacol Exp Ther 1992;262: 119-26.
37. 3 receptors mediate contraction of human central and peripheral airway smooth muscle. Pulmonary Pharm 1990;3:47-51.
38. Fryer AD, Maclagan J. Ipratropium bromide potentiates bronchoconstriction induced by vagal nerve stimulation in the guinea-pig. Eur J Pharmacol 1987;139:187-91.
39. On LS, Boonyongsunchai P, Webb S, Davies L, Calverley PM, Costello RW. Function of pulmonary neuronal M2 muscarinic receptors in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:1320-5.
40. Evans CM, Belmonte KE, Costello RW, Jacoby DB, Gleich GJ, Fryer AD. Substance P-induced airway hyperreactivity is mediated by neuronal M2 receptor dysfunction. Am J Physiol Lung Cell Mol Physiol 2000;279:L477-86.
41. 2 muscarinic receptor dysfunction, and antiviral effects. J Exp Med 1999;190: 1465-78.
42. Costello RW, Evans CM, Yost BL, et al. Antigen-induced hyperreactivity to histamine: role of the vagus nerves and eosinophils. Am J Physiol 1999;276:L709-14.
43. Jacoby DB, Xiao HQ, Lee NH, Chan-Li Y, Fryer AD. Virus-and interferon-induced loss of inhibitory M2 muscarinic receptor function and gene expression in cultured airway parasympathetic neurons. J Clin Invest 1998;102:242-8.
44. Evans CM, Fryer AD, Jacoby DB, Gleich GJ, Costello RW. Pretreatment with antibody to eosinophil major basic protein prevents hyperresponsiveness by protecting neuronal M2 muscarinic receptors in antigen-challenged guinea pigs. J Clin Invest 1997;100:2254-62.
45. Costello RW, Schofield BH, Kephart GM, Gleich GJ, Jacoby DB, Fryer AD. Localization of eosinophils to airway nerves and effect on neuronal M2 muscarinic receptor function. Am J Physiol 1997;273:L93-103.
46. Kahn RM, Okanlami OA, Jacoby DB, Fryer AD. Viral infection induces dependence of neuronal M2 muscarinic receptors on cyclooxygenase in guinea pig lung. J Clin Invest 1996; 98:299-307.
47. Elbon CL, Jacoby DB, Fryer AD. Pretreatment with an antibody to interleukin-5 prevents loss of pulmonary M2 muscarinic receptor function in antigen-challenged guinea pigs. Am J Respir Cell Mol Biol 1995;12:320-8.
48. Fryer AD, Yarkony KA, Jacoby DB. The effect of leukocyte depletion on pulmonary M2 muscarinic receptor function in parainfluenza virus-infected guinea-pigs. Br J Pharmacol 1994;112:588-94.
49. Jacoby DB, Gleich GJ, Fryer AD. Human eosinophil major basic protein is an endogenous allosteric antagonist at the inhibitory muscarinic M2 receptor. J Clin Invest 1993; 91:1314-18.
50. Fryer AD, Jacoby DB. Function of pulmonary M2 muscarinic receptors in antigen-challenged guinea pigs is restored by heparin and poly-L-glutamate. J Clin Invest 1992;90:2292-8.
51. Jacoby DB, Fryer AD. Virus-induced airway hyperresponsiveness - possible involvement of neural mechanisms. Am Rev Respir Dis 1991;144:1422-3.
52. Fryer AD, Jacoby DB. Parainfluenza virus infection damages inhibitory M2 muscarinic receptors on pulmonary parasympathetic nerves in the guinea-pig. Br J Pharmacol 1991;102:267-71.
53. Lammers JW, Barnes PJ, Chung KF. Nonadrenergic, noncholinergic airway inhibitory nerves. Eur Respir J 1992; 5:239-46.
54. Cazzola M, Matera MG, Liccardi G, Sacerdoti G, D’Amato G, Rossi F. Effect of telenzepine, an M1-selective muscarinic receptor antagonist, in patients with nocturnal asthma. Pulm Pharmacol 1994;7:91-7.
55. Saitoh H, Masuda T, Shimura S, Fushimi T, Shirato K. Secretion and gene expression of secretory leukocyte protease inhibitor by human airway submucosal glands. Am J Physiol Lung Cell Mol Physiol 2001;280:L79-87.
56. Tamaoki J, Chiyotani A, Tagaya E, Sakai N, Konno K. Effect of long term treatment with oxitropium bromide on airway secretion in chronic bronchitis and diffuse panbronchiolitis. Thorax 1994;49:545-8.
57. Wanner A. Effect of ipratropium bromide on airway mucociliary function. Am J Med 1986;81:23-7.
58. Cugell DW. Clinical pharmacology and toxicology of ipratropium bromide. Am J Med 1986;81:18-22.
59. Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS. Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis. Drugs 1980;20:237-66.
60. 1. The Lung Health Study. JAMA 1994;272:1497-505.
61. Anderson WM. Hemodynamic and non-bronchial effects of ipratropium bromide. Am J Med 1986;81:45-53.
62. Beasley CR, Rafferty P, Holgate ST. Bronchoconstrictor properties of preservatives in ipratropium bromide (Atrovent) nebuliser solution. Br Med J (Clin Res Ed) 1987;294:1197-8.
63. 3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping. Mol Pharmacol 1994;45:899-907.
64. Takahashi T, Belvisi MG, Patel H, et al. Effect of Ba 679 BR, a novel long-acting anticholinergic agent, noncholinergic neurotransmission in guinea pig and human airways. Am J Respir Crit Care Med 1994;150:1640-5.
65. O’Connor BJ, Towse LJ, Barnes PJ. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am J Respir Crit Care Med 1996;154:876-80.
66. Littner MR, Ilowite JS, Tashkin DP, et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1136-42.
67. van Noord JA, Bantje TA, Eland ME, Korducki L, Cornelissen PJ. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 2000;55:289-94.
68. Calverley PM. The future for tiotropium. Chest 2000;117:67S-9S.
69. Barnes PJ. The pharmacological properties of tiotropium. Chest 2000;117:63S-6S.
70. Maesen FP, Smeets JJ, Sledsens TJ, Wald FD, Cornelissen PJ. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group. Eur Respir J 1995;8:1506-13.
71. Haddad EB, Patel H, Keeling JE, Yacoub MH, Barnes PJ, Belvisi MG. Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea-pig airways. Br J Pharmacol 1999;127:413-20.
72. Oliver G, Schafer EA. The physiological effects of extracts of the suprarenal capsules. J Physiol 1895;18:270-6.
73. Davenport HW. Early history of the concept of chemical transmission of the nerve impulse. The Physiologist 1991; 34:129-90.
74. Ahlquist RPA. A study of the adrenotropic receptors. Am J Physiol 1948;153:586-600.
75. Baraniuk JN, Kowalski ML, Kaliner MA. Relationships between permeable vessels, nerves, and mast cells in rat cutaneous neurogenic inflammation. J Appl Physiol 1990;68:2305-11.
76. Baraniuk JN. Neural control of human nasal secretion. Pulm Pharmacol 1991;4:20-31.
77. Chen Y, Getchell TV, Sparks DL, Getchell ML. Patterns of adrenergic and peptidergic innervation in human olfactory mucosa: age-related trends. J Comp Neurol 1993;334:104-16.
78. Bergendal A, Linden A, Lotvall J, Skoogh BE, Lofdahl CG. Different effects of salmeterol, formoterol and salbutamol on cholinergic responses in the ferret trachea. Br J Pharmacol 1995;114:1478-82.
79. Skoogh BE, Ullman A. Modulation of cholinergic neurotransmission to the airways. Am Rev Respir Dis 1991; 143:1427-8.
80. Xue QF, Maurer R, Engel G. Selective distribution of betaand alpha 1-adrenoceptors in rat lung visualized by autoradiography. Arch Int Pharmacodyn Ther 1983; 266:308-14.
81. Carstairs JR, Nimmo AJ, Barnes PJ. Autoradiographic localisation of beta-adrenoceptors in human lung. Eur J Pharmacol 1984;103:189-90.
82. Carstairs JR, Nimmo AJ, Barnes PJ. Autoradiographic visualization of beta-adrenoceptor subtypes in human lung. Am Rev Respir Dis 1985;132:541-7.
83. Spina D, Rigby PJ, Paterson JW, Goldie RG. Autoradiographic localization of beta-adrenoceptors in asthmatic human lung. Am Rev Respir Dis 1989;140:1410-15.
84. Spina D, Rigby PJ, Paterson JW, Goldie RG. Alpha 1-adrenoceptor function and autoradiographic distribution in human asthmatic lung. Br J Pharmacol 1989;97:701-8.
85. Henry PJ, Rigby PJ, Goldie RG. Distribution of beta 1-and beta 2-adrenoceptors in mouse trachea and lung: a quantitative autoradiographic study. Br J Pharmacol 1990; 99:136-44.
86. Strader CD, Sigal IS, Dixon RA. Mapping the functional domains of the beta-adrenergic receptor. Am J Respir Cell Mol Biol 1989;1:81-6.
87. Johnson M. The beta-adrenoceptor. Am J Respir Crit Care Med 1998;158:S146-53.
88. Collins S, Caron MG, Lefkowitz RJ. From ligand binding to gene expression: new insights into the regulation of G-protein-coupled receptors. Trends Biochem Sci 1992;17: 37-9.
89. Hausdorff WP, Caron MG, Lefkowitz RJ. Turning off the signal: desensitization of beta-adrenergic receptor function. Faseb J 1990;4:2881-9.
90. Svedmyr N. Fenoterol: a beta2-adrenergic agonist for use in asthma. Pharmacology, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy 1985;5:109-26.
91. Heel RC, Brogden RN, Speight TM, Avery GS. Fenoterol: a review of its pharmacological properties and therapeutic efficacy in asthma. Drugs 1978;15:3-32.
92. Brittain RT, Farmer JB, Marshall RJ. Some observations on the adrenoceptor agonist properties of the isomers of salbutamol. Br J Pharmacol 1973;48:144-7.
93. Lulich KM, Goldie RG, Ryan G, Paterson JW. Adverse reactions to beta 2-agonist bronchodilators. Med Toxicol 1986; 1:286-99.
94. 2-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000;162:75-80.
95. Drazen JM, Israel E, Boushey HA, Chinchilli VM, Fahy JV, Fish JE, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med 1996;335:841-7.
96. 2-agonist therapy. Clin Sci (Colch) 1999;96:253-9.
97. Aziz I, Tan KS, Hall IP, Devlin MM, Lipworth BJ. Subsensitivity to bronchoprotection against adenosine monophosphate challenge following regular once-daily formoterol. Eur Respir J 1998;12:580-4.
98. Tan S, Hall IP, Dewar J, Dow E, Lipworth B. Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet 1997;350:995-9.
99. Anderson GP. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator. Life Sci 1993;52:2145-60.
100. Lofdahl CG. Basic pharmacology of new long-acting sympathomimetics. Lung 1990;168:18-21.
101. Johnson M. Salmeterol: a novel drug for the treatment of asthma. Agents Actions Suppl 1991;34:79-95.
102. Johnson M. The pharmacology of salmeterol. Lung 1990;168: 115-19.
103. 2- agonists in asthma therapy. Chest 1998;113:1095-108.
104. Linden A, Rabe KF, Lofdahl CG. Pharmacological basis for duration of effect: formoterol and salmeterol versus short-acting beta 2-adrenoceptor agonists. Lung 1996; 174:1-22.
105. Waldeck B. Some pharmacodynamic aspects on long-acting beta-adrenoceptor agonists. Gen Pharmacol 1996;27: 575-80.
106. Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997;10:815-21.
107. Salter H. On some points in the treatment and clinical history of asthma. Edin Med J 1859;4:1109-15.
108. Butcher RW, Sutherland EW. Adenosine 3'5'-phosphate in biological materials. J Biol Chem 1962;237:1244-50.
109. Yasui K, Hu B, Nakazawa T, Agematsu K, Komiyama A. Theophylline accelerates human granulocyte apoptosis not via phosphodiesterase inhibition. J Clin Invest 1997;100: 1677-84.
110. Okubo Y, Hossain M, Horie S, et al. Inhibitory effects of theophylline and procaterol on eosinophil function. Intern Med 1997;36:276-82.
111. Adachi T, Motojima S, Hirata A, et al. Eosinophil apoptosis caused by theophylline, glucocorticoids, and macrolides after stimulation with IL-5. J Allergy Clin Immunol 1996;98:S207-15.
112. Namovic MT, Walsh RE, Goodfellow C, Harris RR, Carter GW, Bell RL. Pharmacological modulation of eosinophil influx into the lungs of Brown Norway rats. Eur J Pharmacol 1996;315:81-8.
113. Cohan VL, Showell HJ, Fisher DA, et al. in vitro pharmacology of the novel phosphodiesterase type four inhibitor, CP-80633. J Pharmacol Exp Ther 1996;278: 1356-61.
114. Turner CR, Cohan VL, Cheng JB, Showell HJ, Pazoles CJ, Watson JW. The in vivo pharmacology of CP-80, 633, a selective inhibitor of phosphodiesterase 4. J Pharmacol Exp Ther 1996;278:1349-55.
115. Tenor H, Hatzelmann A, Church MK, Schudt C, Shute JK. Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects. Br J Pharmacol 1996;118: 1727-35.
116. Sagara H, Fukuda T, Okada T, Ishikawa A, Makino S. Theophylline at therapeutic concentration suppresses PAF-induced upregulation of Mac-1 on human eosinophils. Clin Exp Allergy 1996;26:16-21.
117. Horiguchi T, Tachikawa S, Kasahara J, et al. Suppression of airway inflammation by theophylline in adult bronchial asthma. Respiration 1999;66:124-7.
118. Momose T, Okubo Y, Horie S, Suzuki J, Isobe M, Sekiguchi M. Effects of intracellular cyclic AMP modulators on human eosinophil survival, degranulation and CD11b expression. Int Arch Allergy Immunol 1998;117:138-45.
119. Spoelstra FM, Berends C, Dijkhuizen B, de Monchy JG, Kauffman HF. Effect of theophylline on CD11b and L-selectin expression and density of eosinophils and neutrophils in vitro. Eur Respir J 1998;12:585-91.
120. Peleman RA, Kips JC, Pauwels RA. Therapeutic activities of theophylline in chronic obstructive pulmonary disease. Clin Exp Allergy 1998;28:53-6.
121. Belman MJ. Effects of aminophylline on diaphragmatic fatigue during acute respiratory failure. Am Rev Respir Dis 1984;130:695.
122. Vires N, Aubier M, Murciano D, Fleury B, Talamo C, Pariente R. Effects of aminophylline on diaphragmatic fatigue during acute respiratory failure. Am Rev Respir Dis 1984;129:396-402.
123. Cooling DS. Theophylline toxicity. J Emerg Med 1993;11: 415-25.
124. Sessler CN. Theophylline toxicity: clinical features of 116 consecutive cases. Am J Med 1990;88:567-76.
125. Tsiu SJ, Self TH, Burns R. Theophylline toxicity: update. Ann Allergy 1990;64:241-57.
126. Hardman JG, Goodman Gilman A, Limbird LE. The Pharmacological Basis of Therapeutics, 9th edn. McGraw-Hill, New York, 1996.
127. Houslay MD, Milligan G. Tailoring cAMP-signalling responses through isoform multiplicity. Trends Biochem Sci 1997;22: 217-24.
128. Weishaar RE, Cain MH, Bristol JA. A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem 1985;28:537-45.
129. Thompson WJ, Appleman MM. Characterization of cyclic nucleotide phosphodiesterases of rat tissues. J Biol Chem 1971;246:3145-50.
130. Thompson WJ, Appleman MM. Multiple cyclic nucleotide phosphodiesterase activities from rat brain. Biochemistry 1971;10:311-16.
131. Bernareggi MM, Belvisi MG, Patel H, Barnes PJ, Giembycz MA. Anti-spasmogenic activity of isoenzymeselective phosphodiesterase inhibitors in guinea-pig trachealis. Br J Pharmacol 1999;128:327-36.
132. Challiss RA, Adams D, Mistry R, Nicholson CD. Modulation of spasmogen-stimulated Ins(1, 4, 5)P3 generation and functional responses by selective inhibitors of types three and four phosphodiesterase in airways smooth muscle. Br J Pharmacol 1998;124:47-54.
133. Spina D, Ferlenga P, Biasini I, et al. The effect duration of selective phosphodiesterase inhibitors in the guinea pig. Life Sci 1998;62:953-65.
134. 1. Biochem Pharmacol 2001;61:1551-9.
135. Hatzelmann A, Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J Pharmacol Exp Ther 2001;297:267-79.
136. Cooper N, Teixeira MM, Warneck J, et al. A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivo. Br J Pharmacol 1999;126:1863-71.
137. Blease K, Burke-Gaffney A, Hellewell PG. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases three and four. Br J Pharmacol 1998;124:229-37.
138. Gantner F, Tenor H, Gekeler V, Schudt C, Wendel A, Hatzelmann A. Phosphodiesterase profiles of highly purified human peripheral blood leukocyte populations from normal and atopic individuals: a comparative study. J Allergy Clin Immunol 1997;100:527-35.
139. Torphy TJ, Page C. Phosphodiesterases: the journey towards therapeutics. Trends Pharmacol Sci 2000;21:157-9.
140. Barnette MS, Underwood DC. New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease. Curr Opin Pulm Med 2000;6:164-9.
141. Barnette MS. Phosphodiesterase four (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD). Prog Drug Res 1999;53:193-229.
142. Jacobitz S, McLaughlin MM, Livi GP, Burman M, Torphy TJ. Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding. Mol Pharmacol 1996; 50:891-9.
143. Zeller E, Stief HJ, Pflug B, Sastre-y-Hernandez M. Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry 1984;17:188-90.
144. Wachtel H. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3', 5'-monophosphate phosphodiesterase inhibitors. Neuropharmacology 1983;22:267-72.
145. Glover ED, Glover PN. Pharmacologic treatments for the nicotine dependent smoker. Am J Health Behav 2001;25: 179-82.
146. Panchagnula R, Jain AK, Pillai O, Jaiswal J. Nicotine transdermal systems: pharmaceutical and clinical aspects. Methods Find Exp Clin Pharmacol 2000;22:299-308.
147. Silagy C, Mant D, Fowler G, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2000;CD000146.
148. Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol 1997;29:1422-31.
149. Pomerleau OF. Nicotine and the central nervous system: biobehavioral effects of cigarette smoking. Am J Med 1992;93:2S-7S.
150. Schneider NG, Lunell E, Olmstead RE, Fagerstrom KO. Clinical pharmacokinetics of nasal nicotine delivery. A review and comparison to other nicotine systems. Clin Pharmacokinet 1996;31:65-80.
151. Tonnesen P. Smoking cessation: nicotine replacement, gums and patches. Monaldi Arch Chest Dis 1999;54:489-94.
152. Prochazka AV. New developments in smoking cessation. Chest 2000;117:169S-75S.
153. Lief HI. Bupropion treatment of depression to assist smoking cessation. Am J Psychiatry 1996;153:442.
154. Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997;337:1195-202.
155. Hayford KE, Patten CA, Rummans TA, et al. Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. Br J Psychiatry 1999;174:173-8.
156. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;340: 685-91.
157. Pasternak M. Sustained-release bupropion for smoking cessation. N Engl J Med 1998;338:619-20.
158. Ferris RM, Beaman OJ. Bupropion: a new antidepressant drug, the mechanism of action of which is not associated with down-regulation of postsynaptic beta-adrenergic, serotonergic (5-HT2), alpha 2-adrenergic, imipramine and dopaminergic receptors in brain. Neuropharmacology 1983;22:1257-67.
159. Ferris RM, Cooper BR, Maxwell RA. Studies of bupropion’s mechanism of antidepressant activity. J Clin Psychiatry 1983;44:74-8.
160. Cooper BR, Hester TJ, Maxwell RA. Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo. J Pharmacol Exp Ther 1980;215:127-34.
161. Tashkin D, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001;357:1571-5.